Chinese coronavirus vaccine approved for use in country's military after clinical trials




Chinese coronavirus vaccine approved for use in country\
Chinese coronavirus vaccine approved for use in country\'s military after clinical trials  

China's military has approved a coronavirus vaccine developed by its own research staff and a Chinese biotech firm, it was announced on Monday.

The vaccine was given the green light for use by troops after trials proved it was both safe and effective, said CanSino Biologics, the biotech firm involved.

However, its use for the time being will be restricted to military personnel, who offer a tighter medical control group than the general public.

The vaccine candidate, named Ad5-nCoV, was developed jointly by CanSino and the Beijing Institute of Biotechnology in the Academy of Military Medical Sciences. It has been in development since March.

CanSino said the results showed the vaccine candidate has potential to prevent diseases caused by the coronavirus, which has killed half a million people globally.

The company added that it was not yet possible to say if it could be a commercial success, which would depend on being able to produce the vaccine cheaply as well as safely.

It declined to comment on whether the vaccine would be compulsory or optional for China's two million military personnel.

The militaries of major powers are often involved in the research for vaccines as they often have well-resourced research departments tasked with examining bio-hazard threats.

The US Army is also working on a vaccine which it hopes to have ready by the end of the year.

Martin Bricknell, a former Surgeon General of the British Armed Forces who is now Professor of Conflict, Health and Military Medicine at London's King's College, told The Telegraph that Covid-19 outbreaks on board US aircraft carriers had demonstrated the threat of the virus to the armed forces.

However, he added: "Any decision by a nation to preferentially vaccinate its armed forces over more susceptible members of its population would be an international signal of its prioritisation of military security over health security."

No vaccine has yet been approved for commercial use against the illness caused by the new coronavirus, but over a dozen vaccines from more than 100 candidates globally are being tested in humans.

China, which has lost 4,600 people to the outbreak since its outset in the city of Wuhan, is a leading player in the global scientific race.

The Ad5-nCoV is one of the eight vaccine candidates being developed by Chinese companies and researchers approved to be moved into human trials for the respiratory disease.

Two weeks ago, a Chinese drug firm, China National Biotec Group, announced positive early results of a vaccine against the coronavirus, claiming it induced an immune response in 100 per cent of those who were given it.

In Britain, trials are underway at both Oxford and Imperial College Universities, with hopes that the ZD1222 vaccine may be ready for UK citizens by September.

If effective, it would allow people to leave their homes, go back to work, and rebuild the economy.

COMMENTS

More Related News

Chinese company says coronavirus vaccine ready by early 2021
Chinese company says coronavirus vaccine ready by early 2021

A Chinese pharmaceutical company said Thursday the coronavirus vaccine it is developing should be ready by early 2021 for distribution worldwide, including the United States. Yin Weidong, the CEO of SinoVac, vowed to apply to the U.S. Food and Drug Administration to sell CoronaVac in the United States if it passes its third and final round of testing in humans. Yin said he personally has been given the experimental vaccine.

China
China's Sinovac eyes coronavirus vaccine distribution in South America
  • US
  • 2020-09-24 09:53:47Z

China's Sinovac Biotech hopes to supply its experimental coronavirus vaccine to more South American countries by outsourcing some manufacturing procedures to a partner in Brazil, its chief executive said on Thursday. Global vaccine makers, such as Sinovac and AstraZeneca, have partnered with Brazil to conduct late-stage trials of their vaccine candidates in South America's largest nation, battling with the third highest tally of infections worldwide.

Mike Pompeo urges US states to beware of China
Mike Pompeo urges US states to beware of China's 'sinister' attempts at engagement
  • World
  • 2020-09-24 09:30:00Z

US Secretary of State Mike Pompeo called on American state governments to reject appeals from China for closer ties and asked them to cooperate more with Taiwan.Warning about Beijing's attempts to sidestep road blocks erected by Washington on the federal level, Pompeo told state lawmakers in Madison, Wisconsin, that overtures from Chinese diplomats, Chinese nationals or "Americans working with [Chinese Communist Party]-linked interests" were often part of a plot to further "Beijing's form of authoritarianism".Chinese President Xi Jinping "knows that the federal government is pushing back against the CCP's malign influence. He sees that here in the US, and...

China
China's CNBG to donate 200,000 coronavirus vaccine doses to medics in Wuhan
  • US
  • 2020-09-24 06:34:02Z

China National Biotec Group (CNBG) said on Thursday it will donate 200,000 doses of its candidate coronavirus vaccine to the central city of Wuhan, where the virus first emerged late last year. Hundreds of thousands of people have taken experimental vaccines in China before clinical trials are completed, thanks to an emergency use programme launched in July to protect essential workers and limited groups of people facing high infection risk, raising safety concern among experts. The 200,000 shots of a vaccine developed by CNBG's Wuhan unit, enough to inoculate 100,000 people, will be used to protect medical workers in the city, CNBG said in a social media post.

WeWork sells majority stake in Chinese entity, seeks localization
WeWork sells majority stake in Chinese entity, seeks localization

Four years after its foray into the Chinese market followed by rapid and cash-hemorrhaging expansion, WeWork decided to wind down its involvement in the country. WeWork's Chinese unit has secured a $200 million investment led by Shanghai-based equity firm Trustbridge Partners, which first backed WeWork China in its Series B round in 2018, the American co-working giant announced. What the release didn't emphasize is that the latest financing effectively makes Trustbridge Partners the controlling shareholder, leaving WeWork with a minority stake in its Chinese entity.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Latin America